Abstract:Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths in the United States and worldwide. Receptor tyrosine kinase (RTK) signaling through Epidermal Growth Factor Receptor (EGFR) has been shown to play a key role in the development and progression of NSCLC. Two activating mutations within EGFR, L858R and del19, have been demonstrated to lead to oncogene addiction and have also been shown to confer sensitivity to targeted EGFR inhibitors (e.g. erlotinib and gefitinib). Earlier work has demonstrated a crucial role for the EGFR downstream effector c-Src in the upregulation of Vascular Endothelial Growth Factor (VEGF), a HIF-1\#945; regulated gene. We have identified a correlation between mutant EGFR and elevated HIF-1\#945; protein levels. Thus, we hypothesized that c-Src may be a critical downstream effector of mutant EGFR and may have a central role in the upregulation of HIF-1\#945; signaling by activated EGFR. NSCLC cell lines were treated with erlotinib to demonstrate a role for mutant EGFR in the upregulation of HIF-1\#945; and subsequently VEGF protein levels. HCC827 NSCLC cells, expressing the EGFR sensitizing mutant, had significantly reduced HIF-1\#945; protein levels and VEGF secretion when treated with the EGFR inhibitor, whereas, A549 cells, expressing the wild-type EGFR, were minimally effected by erlotinib treatment, compared their respective untreated controls. Furthermore, transient transfection with del19 EGFR led to increased VEGF promoter activity as demonstrated by a luciferase assay. These data demonstrate a central role for mutant EGFR signaling in the upregulation of HIF-1\#945; protein levels and VEGF secretion. Hence, signaling through mutant EGFR uncouples the normal regulation of HIF-1\#945; from hypoxia leading to aberrant expression of the angiogenic growth factor, VEGF. To identify critical signaling pathways potentially involved in the EGFR-induced up-regulation of HIF-1\#945;, multiple inhibitors were utilized. Inhibition of Mek did not affect HIF-1\#945; protein levels compared to controls, whereas inhibition of phosphotidylinositol-3-kinase (PI3K) led to a 50% reduction in HIF-1\#945; protein levels versus untreated cells. The Src family inhibitor PP2 led to a complete reduction of HIF-1\#945; protein, and similar results were seen with erlotinib. Moreover, erlotinib and PP2 led to a partial reduction of HIF-2\#945; protein levels. Collectively, our data demonstrate that NSCLC cells expressing activating mutations in EGFR have elevated HIF-1\#945; protein levels and that the c-Src signaling pathway may play a central role in the uncoupling of HIF-1\#945; signaling from hypoxia-induced regulation. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4216.

Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII.

Weak Binding to E3 Ubiquitin Ligase C‐cbl Increases EGFRvA Protein Stability

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer

Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors

Neuregulin-Induced Erbb3 Downregulation is Mediated by A Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1

A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition

Phosphorylated Insulin-Like Growth Factor 1 Receptor is Implicated in Resistance to the Cytostatic Effect of Gefitinib in Colorectal Cancer Cells

The Exon 19-Deleted EGFR Undergoes Ubiquitylation-Mediated Endocytic Degradation Via Dynamin Activity-Dependent and -Independent Mechanisms

Abstract 5874: Phenotypic plasticity of TKI resistance reprograms cytoskeleton organization through cadherin-catenin and integrin pathways

The clathrin adaptor complex-1 and Rab12 regulate post-golgi trafficking of WT epidermal growth factor receptor (EGFR)

Endocytosis of Ubiquitylation-Deficient EGFR Mutants via Clathrin-Coated Pits is Mediated by Ubiquitylation

Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity

Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor

Abstract #4216: A Role for C-Src in EGFR-induced Upregulation of HIF-1\#945;

EGFR and EGFRvIII coopt host defense pathways, promoting progression in glioblastoma

TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target

Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases

EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation

10-14-2014 EGFR Phosphorylates and Inhibits Lung Tumor Suppressor GPRC 5 A in Lung Cancer